Clinical observation on the combination of camrelizumab andintensity modulated radiotherapy in the treatment of advanced esophageal squamous cell carcinoma patients
Objective:To analyze the therapeutic effect of camrelizumab combined with intensity-modulated radiotherapy(IMRT)in patients with advanced esophageal squamous cell carcinoma(ESCC).Methods:74 patients with advanced esophageal squamous cell carcinoma treated at our hospital from January 2020 to January 2022 were selected and randomly divided into two groups,with 37 patients in each group.The control group received intensity-modulated radiation therapy using a medical linear accelerator[to determine the gross tumor area(GTV),clinical target volume(CTV),and planned target volume(PTV)],whereas the observation group received additional treatment with carolizumab(intravenous infusion,200 mg/dose,1 dose/2 weeks)for 6 consecutive weeks.Clinical efficacy,serum tumor markers,immune status,and short-term survival rates were compared between the two groups.Results:The objective remission rate in the observation group was significantly higher than that in the control group(P＜0.05).Before treatment,there was no statistically significant difference between the two groups in the levels of carcinoembryonic antigen(CEA),carbohydrate antigen125(CA125),carbohydrate antigen 153(CA153),CD3+,CD4+,and CD8+(P＞0.05).After treatment,CEA,CA125,CA153,and CD8+ levels in both groups were lower than those before treatment,while CD3+ and CD4+ levels were higher than those before treatment.In addition,CEA,CA125,CA153,and CD8+ levels in the observation group were lower than those in the control group,whereas CD3+ and CD4+ levels were higher in the observation group than in the control group(P＜0.05).The short-term survival rate of the observation group was slightly higher than that of the control group;however,the difference was not statistically significant(P＞0.05).Logistic regression analysis showed that the treatment methods had an impact on post-treatment CEA,CA125,and CD8+(OR＞1,P＜0.05).Conclusion:The combination of camrelizumab and IMRT is effective in the treatment of patients with advanced esophageal squamous cell carcinoma.It can effectively reduce the levels of body tumor markers,improve immune status,and improve the short-term survival rate to some extent.
NETL
NSTL
万方数据
